- Centers & Specialties
- Clinical Interests
- New cancer drugs
- Breast cancer
- Non-Hodgkin's lymphoma (NHL)
- Medical Education
- MD, Harvard Medical School
- Residency, Brigham and Women's Hospital
- Fellowship, National Cancer Institute|Fellowship, Yale-New Haven Hospital
- Board Certifications
- Medical Oncology
- Internal Medicine
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet (non par)
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Dr. Chabner has had extensive experience in the field of cancer drug discovery and development. During his career at the National Cancer Institute, he served as a Senior Investigator in the Laboratory of Chemical Pharmacology, Chief of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program, and Director of the Division of Cancer Treatment.
At the NCI, he maintained an active laboratory program in cancer pharmacology, and led the development of Taxol. His research contributed significantly to the development of high dose chemotherapy regimens, and to standard therapies for lymphoma.
Dr. Chabner is a senior editor for the Oncologist and serves on the executive advisory boards for some of the industry's leading innovators in drug development. In 2006, Dr. Chabner received a presidential appointment to the National Cancer Advisory Board at the NCI.
In February, faculty from the MGH Cancer Center and the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) launched the Program for Enhanced Training in Cancer (POETIC).
Faculty from the Mass General Cancer Center and Beth-Israel Deaconess Medical Center launched the Program for Enhanced Training in Cancer (POETIC), a fellowship exchange program with clinical oncology fellows from Cape Town University, and Ocean Road Cancer Center in Tanzania.
Bruce Chabner, MD, director of Clinical Research for the MGH Cancer Center, was the recipient of an honorary Doctorate of Medical Sciences from the Queen’s University of Belfast, Northern Ireland.
MGH Hotline 12.10.10 A named chair is one of the highest honors a physician may receive in his or her lifetime.
55 Fruit Street
Boston, MA 02114-2696